Valisure Benzoyl Peroxide Update 2026: Evidence and Open Questions

As of 2026, benzoyl peroxide acne products remain widely sold after limited FDA recalls and dismissal of a major benzene lawsuit. Evidence shows benzene can form in some products, but FDA testing found most products clean and added cancer risk very low. Benzoyl peroxide (BPO) is a common acne ingredient that fights acne bacteria and helps clear pores. Benzene is a separate chemical that can form as BPO breaks down, especially in old or warm tubes.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

What did Valisure report?
What did FDA testing find?
Why do the two sets of results differ?
What did the court decide about warning claims?
How should you handle BPO in 2026?

What did Valisure report?

Valisure filed a March 5-6, 2024 citizen petition asking FDA to recall and suspend sales of benzoyl peroxide acne products. The lab said it found benzene in 94 of 99 BPO products tested. Some results exceeded 800 times FDA's 2 ppm conditional limit, according to Valisure's March 2024 newsroom report.

A peer-reviewed follow-up by Valisure, Yale and Long Island University authors tested sealed retail products at room temperature. It found 38 of 111 products already exceeded FDA's 2 ppm benzene limit. That result pointed to contamination before heating or misuse.

What did FDA testing find?

FDA independently tested 95 BPO acne products and reported a different picture on March 11, 2025. More than 90% had undetectable or extremely low benzene, with substantially fewer positives than Valisure suggested, the FDA said in its March 2025 testing update. FDA sought retail-level voluntary recalls for six elevated lots plus a separate Zapzyt gel recall. The list included La Roche-Posay Effaclar Duo lot MYX46W, two Proactiv creams, two Walgreens products and SLMD lotion.

CeraVe was not listed, according to FactCrescendo summarizing FDA. FDA also weighed long-term risk from the recalled lots. Even with daily use for decades, the added cancer risk was very low, according to Dermatology Advisor reporting FDA. Risk centered on regular users of the recalled lots near expiry.

Why do the two sets of results differ?

The main gap is test method. Valisure emphasized heated incubation at 37°C and 50°C plus air-phase benzene. FDA tested products at room temperature and found most market products clean.

That leaves one open issue for shoppers. The Journal and FDA work agree benzene can appear, but the speed of buildup during normal store and home storage is still unresolved, according to Acne Action's 2026 position statement. Heat clearly accelerates BPO breakdown, while cool, fresh stock looks cleaner in FDA's data.

What did the court decide about warning claims?

A consolidated suit alleged L'Oreal failed to warn that CeraVe and La Roche-Posay BPO products could form benzene. Judge Analisa Torres in the Southern District of New York dismissed the case with prejudice.

State failure-to-warn claims were preempted by federal drug labeling law, the court held, according to Bloomberg Law's September 2026 report. Federal rules control what a drug label must say. A state lawsuit cannot require a different acne-drug warning.

How should you handle BPO in 2026?

Use lot, date and storage to cut exposure. Check FDA's March 2025 recall list first, keep current tubes at cool room temperature, and do not save half-used or expired acne creams. Bring the tube and expiry date to your visit so the clinician can check the recall list with you.

Match brand, lot and expiry against FDA's March 2025 recall list
Store BPO at cool room temperature, away from heat and humidity
Discard expired tubes and pumps, even if product remains
Ask a clinician about non-BPO options if you use BPO daily or feel concerned